BRIEF published on 05/04/2026 at 18:10, 19 days 11 hours ago DNXcorp postpones the publication of its 2025 annual financial report Euronext Growth Luxembourg DNXcorp Publication Postponed Financial Report 2025
BRIEF published on 05/04/2026 at 18:10, 19 days 11 hours ago DNXcorp reporte la publication de son rapport financier annuel 2025 Euronext Growth Luxembourg DNXcorp Publication Reportée Rapport Financier 2025
PRESS RELEASE published on 05/04/2026 at 18:05, 19 days 11 hours ago COMMUNIQUÉ SUR LE REPORT DE LA PUBLICATION DU RAPPORT FINANCIER ANNUEL 2025 DNXcorp annonce le report de la publication de son rapport financier annuel 2025 dans l'attente des rapports signés du réviseur d'entreprises Rapport Financier Report Publication DNXcorp Attente
BRIEF published on 04/30/2026 at 18:10, 23 days 11 hours ago DNXcorp's 2025 Results: Review and Outlook Revenue Treasury Profitability Crypto-assets 2025 Results
BRIEF published on 04/30/2026 at 18:10, 23 days 11 hours ago Résultats 2025 de DNXcorp : Bilan et Perspectives Chiffre D'affaires Rentabilité Trésorerie Crypto-actifs Résultats 2025
PRESS RELEASE published on 04/30/2026 at 18:05, 23 days 11 hours ago Résultats 2025 DNXcorp annonce chiffre d'affaires en hausse de 5,0% en 2025 avec réserve en Bitcoins. Résultat opérationnel stable malgré perte de valeur sur cryptoactifs Chiffre D'affaires Hausse DNXcorp Bitcoins Cryptoactifs
BRIEF published on 12/18/2025 at 18:10, 5 months 5 days ago DNXCORP : Mises en examen dans le cadre d'une procédure judiciaire Enquête Judiciaire DNXcorp Conséquences Financières Mises En Examen Services Administratifs
BRIEF published on 12/18/2025 at 18:10, 5 months 5 days ago DNXCORP: Charged in legal proceedings Judicial Investigation DNXcorp Administrative Services Financial Consequences Indictments
PRESS RELEASE published on 12/18/2025 at 18:05, 5 months 5 days ago Information réglementée - Publication d'informations privilégiées Communiqué de presse DNXCORP : Mises en examen de dirigeants suite à une procédure judiciaire, pas d'impact sur les activités actuelles. Suivi attentif des développements. Informations réglementées Informations Réglementées DNXcorp Activités Procédure Judiciaire Mises En Examen
BRIEF published on 10/21/2025 at 18:10, 7 months 2 days ago DNXcorp publie son rapport financier du premier semestre 2025 Finance Bourse 2025 Rapport DNXcorp
Published on 05/23/2026 at 19:45, 9 hours 57 minutes ago Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 1 day 2 hours ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 1 day 2 hours ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 1 day 3 hours ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 1 day 3 hours ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/24/2026 at 05:35, 6 minutes ago CGTN: Xizang at 75: Development and culture create a 'miracle on Earth'
Published on 05/23/2026 at 16:30, 13 hours 11 minutes ago HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 13 hours 45 minutes ago EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day 7 hours ago Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 1 day 7 hours ago Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:35, 1 day 10 hours ago PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 1 day 11 hours ago Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 1 day 11 hours ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 16 hours ago Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 1 day 16 hours ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
